VA-REGULA
MWC attracts tens of thousands of visitors, including representatives of mobile operators, device manufacturers, technology providers, vendors, and content owners. To ensure everyone's safety, the GSMA has traditionally conducted thorough registration and ID validation processes for each attendee.
For many years, the ID validation process was done on-site at the venue, which caused queues and long wait times. With the advent of the pandemic in 2020, and attendance now regularly exceeding 100,000, the GSMA had to find a contactless solution to remove the need to have attendees wait in large numbers to collect badges and have their ID validated. To address these issues and improve the efficiency of the registration process, the GSMA decided to make it totally remote and digital, so that all attendees could swiftly get access to the venue through the entry gates. Any solution would also need to enable quick and efficient international document recognition, because attendees come from all over the world.
To achieve their goal, the GSMA ran an extensive competitive tender process to find the best technology solution. Ultimately, they chose a complete, single-vendor solution by Regula which includes Regula Document Reader SDK and Regula Face SDK. Natively integrated, these solutions facilitate a smooth customer journey and rapid onboarding through seamless and secure identity verification, eliminating the possibility of fraud.
Having successfully piloted Regula products during MWC Barcelona 2021, the GSMA fully transitioned to digital visitor registration and ID validation. After several years of collaboration, this long-term partnership led to a significant enhancement of the visitor registration process, enabling a fast and convenient user experience. Now, Regula Document Reader SDK and Regula Face SDK are easily integrated into the MWC’s existing registration platform for full-fledged production use.
Now, as part of the registration process, an MWC visitor simply uploads their ID on the official website. The identity document is automatically scanned by Regula Document Reader SDK. The solution instantly recognizes the document type, reads its data, and verifies its authenticity with multiple cross-checks. Not only does it streamline the verification process (checks are completed in seconds), but it also minimizes the chance of missing compromised IDs.
Further, an MWC attendee has the opportunity to provide their selfie, which is rapidly captured by Regula Face SDK for user verification.
With the industry’s largest and most comprehensive identity document template database, which contains over 13,600 templates from 249 countries and territories, Regula supports the verification of nearly any identity document from any part of the world. Taking into account MWC attendees’ geographical spread, this ability significantly facilitates the registration process.
With Regula’s complete IDV solution, the GSMA managed to create a custom, smooth, and seamless registration experience for all MWC attendees. During the Barcelona event in 2024, Regula solutions helped to efficiently validate more than 100,000 visitors – all of them registered online beforehand, so there was no need to queue at the venue.
"Our collaboration with GSMA for MWC highlights the power of digital transformation in handling large-scale international events. By integrating our advanced ID verification technologies, not only did we enhance the security and efficiency of the registration process, but also ensured a seamless experience for attendees," says Ihar Kliashchou, Chief Technology Officer at Regula.
“The digital identity verification process has revolutionized the visitor experience, allowing more than 100,000 individuals to register and access the world’s leading connectivity event swiftly, safely, and without interruption," states Xavi Casals, Director of Technology, Innovation & Customer Experience at GSMA.
For more details on the business case, please visit the Regula website.
About GSMA
The GSMA is a global organisation unifying the mobile ecosystem to discover, develop and deliver innovation foundational to positive business environments and societal change. Our vision is to unlock the full power of connectivity so that people, industry and society thrive. Representing mobile operators and organisations across the mobile ecosystem and adjacent industries, the GSMA delivers for its members across three broad pillars: Connectivity for Good, Industry Solutions and Events.
Find out more at gsma.com.
About Regula
Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security or speed. Regula was repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.
Learn more at www.regulaforensics.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240514134027/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom